René Mathiasen

Dr. René Mathiasen


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2021 in The Lancet Child & Adolescent Health
Verified
Journal Article
Closed access
JGJonathan Kjær Grønbæk
Jonathan Kjær Grønbæk
MWMorten Wibroe
Morten Wibroe
STSebastian Toescu
Sebastian Toescu
RFRadek Frič
Radek Frič
BTBirthe Lykke Thomsen
Birthe Lykke Thomsen
PLPäivi Lähteenmäki
Päivi Lähteenmäki

21 June 2017 in BMC Cancer
Verified
Journal Article
Open access
PDF file
MWMorten Wibroe
Morten Wibroe
JCJohan Cappelen
Johan Cappelen
Charlotte CastorCharlotte Castor
Charlotte Castor
NCNiels Clausen
Niels Clausen
PGPernilla Grillner
Pernilla Grillner
MJMarianne Juhler
Marianne Juhler
Central nervous system tumours constitute 25% of all childhood cancers; more than half are located in the posterior fossa and surgery is usually part of therapy. One of the most disabling late effects of posterior fossa tumour surgery is the cerebellar mutism syndrome (CMS) which has been reported in up to 39% of the patients but the exact incidence is uncertain since milder cases may be unrecognized. Recovery is usually incomplete. Reported risk factors are tumour type, midline location and brainstem involvement, but the exact aetiology, surgical and other risk factors, the clinical course and strategies for prevention and treatment are yet to be determined. This observational, prospective, multicentre study will include 500 children with posterior fossa tumours. It opened late 2014 with participation from 20 Nordic and Baltic centres. From 2016, five British centres and four Dutch centres will join with a total annual accrual of 130 patients. Three other major European centres are invited to join from 2016/17. Follow-up will run for 12 months after inclusion of the last patient. All patients are treated according to local practice. Clinical data are collected through standardized online registration at pre-determined time points pre- and postoperatively. Neurological status and speech functions are examined pre-operatively and postoperatively at 1–4 weeks, 2 and 12 months. Pre- and postoperative speech samples are recorded and analysed. Imaging will be reviewed centrally. Pathology is classified according to the 2007 WHO system. Germline DNA will be collected from all patients for associations between CMS characteristics and host genome variants including pathway profiles. Through prospective and detailed collection of information on 1) differences in incidence and clinical course of CMS for different patient and tumour characteristics, 2) standardized surgical data and their association with CMS, 3) diversities and results of other therapeutic interventions, and 4) the role of host genome variants, we aim to achieve a better understanding of risk factors for and the clinical course of CMS - with the ultimate goal of defining strategies for prevention and treatment of this severely disabling condition. Clinicaltrials.gov : NCT02300766 , date of registration: November 21, 2014.

4 February 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ADAnne Louise Damgaard
Anne Louise Damgaard
BHBo Mølholm Hansen
Bo Mølholm Hansen
RMRené Mathiasen
René Mathiasen
FBFrederik Buchvald
Frederik Buchvald
TLTheis Lange
Theis Lange
GGGorm Greisen
Gorm Greisen
Preterm birth is associated with increased risk of asthma-like symptoms and purchase of prescription asthma medication in childhood. We investigated whether this association persists into adulthood and whether it is affected by accounting for neonatal respiratory morbidity (acute respiratory disease and bronchopulmonary dysplasia). A national cohort of all infants born in Denmark in the period 1980–2009 was included in this register study. Data on purchase of asthma medication (combination of inhaled β-2 agonists and other drugs for obstructive airway disease) in 2010–2011 were obtained from the Danish National Prescription Registry. Associations between gestational age (GA), neonatal respiratory morbidity and a cross-sectional evaluation of asthma medication purchase were explored by multivariate logistic regressions. A full dataset was obtained on 1,790,241 individuals, 84.6% of all infants born in the period. Odds-ratios (95% CI) for the association between GA and purchase of asthma medication during infancy were: 3.86 (2.46–6.04) in GA 23–27 weeks, 2.37 (1.84–3.04) in GA 28–31 weeks and 1.59 (1.43–1.77) in GA 32–36 weeks compared to term infants with GA 37–42 weeks. Associations weakened in older age groups and became insignificant in young adults born extremely and very preterm with odds-ratios: 1.41 (0.63–3.19) and 1.15 (0.83–1.60) in GA 23–27 and 28–31 respectively. When adjusting for neonatal respiratory morbidity, the associations weakened but persisted both in childhood and adolescence. There was a strong dose-response association between gestational age and the purchase of prescription asthma medication in infancy and childhood. This association weakened during adolescence and was mostly non-significant in young adulthood. The increased risk of prescription asthma medication purchase in ex-preterm children could only partly be explained by neonatal respiratory morbidity.

20 July 2020 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
AEAstrid Eliasen
Astrid Eliasen
MAMikkel Kramme Abildtoft
Mikkel Kramme Abildtoft
NKNiels Steen Krogh
Niels Steen Krogh
CRCatherine Rechnitzer
Catherine Rechnitzer
JBJesper Sune Brok
Jesper Sune Brok
Kim Peder DalhoffKim Peder Dalhoff
Kim Peder Dalhoff
Background: Nausea and vomiting are common and distressing side effects for children receiving chemotherapy. Limited evidence is available to guide antiemetic recommendations; therefore, prospective and reliable evaluation of antiemetic efficacy is needed. Smartphone apps can be used to effortlessly and precisely collect patient-reported outcomes in real time. Objective: Our objective was to develop a smartphone app to monitor nausea and vomiting episodes in pediatric cancer patients aged 0 to 18 years and to test its usability and adherence to its use. Methods: We used a user-centered design process and the evolutionary prototype model to develop and evaluate the app. Multidisciplinary group discussions and several rounds of patient feedback and modification were conducted. We translated the validated Pediatric Nausea Assessment Tool to assess nausea severity in children aged 4 to 18 years. The child’s own term for nausea was interactively incorporated in the nausea severity question, with response options expressed as 4 illustrative faces. Parent-reported outcomes were used for children aged 0 to 3 years. Reminders were sent using push notifications in order to ensure high response rates. Children aged 0 to 18 years who were undergoing chemotherapy were recruited from the Department of Pediatric Oncology at Copenhagen University Hospital Rigshospitalet to evaluate the app. Results: The app’s most important function was to record nausea severity in children. After assistance from a researcher, children aged 4 to 18 years were able to report their symptoms in the app, and parents were able to report symptoms for their children aged 0 to 3 years. Children (n=20, aged 2.0-17.5 years) and their parents evaluated the app prospectively during a collective total of 60 chemotherapy cycles. They expressed that the app was user-friendly, intuitive, and that the time spent on data entry was fair. The response rates were on average 92%, 93%, and 80% for the day before, the first day of, and the next 3 days after chemotherapy, respectively. Researchers and clinicians were able to obtain an overview of the patient’s chemotherapy dates and responses through a secure and encrypted web-based administrative portal. Data could be downloaded for further analysis. Conclusions: The user-friendly app could be used to facilitate future pediatric antiemetic trials and to refine antiemetic treatment during chemotherapy.

29 October 2014 in Developmental Medicine & Child Neurology
Verified
Journal Article
Open access
PDF file
PVPernille Kure Vandborg
Pernille Kure Vandborg
BHBo Mølholm Hansen
Bo Mølholm Hansen
GGGorm Greisen
Gorm Greisen
RMRené Mathiasen
René Mathiasen
FKFrederikke Kasper
Frederikke Kasper
FEFinn Ebbesen
Finn Ebbesen
Aim: To investigate whether infants with neonatal hyperbilirubinaemia but without intermediate or advanced bilirubin encephalopathy develop long‐term sequelae, with impairment of motor development, executive function, or hearing.Method: This nested double‐cohort study included 167 exposed children (107 males, 60 females) born in Denmark 2000 to 2005 at gestational age ≥35 weeks with a total serum bilirubin ≥450 μmol/L (26.3mg/dL) and 163 age‐, sex‐, and gestational age‐matched unexposed children (103 males, 60 females). The children were examined at a mean age of 7.7 years (SD 1.7y) using the Movement Assessment Battery for Children–Second Edition (MABC‐2), pure tone audiometry, and the Behavioural Regulation Inventory of Executive Function (BRIEF) questionnaire.Results: The follow‐up rate was 70% of the eligible infants in the exposed group and 45% in the unexposed group. Mean difference was −0.2 (95% confidence interval [CI] −1.1 to 0.8) in adjusted standard score for MABC‐2 and 0.3 (95% CI −2.9 to 3.5) in adjusted BRIEF executive composite standard score. No children had significant hearing impairment or a diagnosis of cerebral palsy, attention‐deficit–hyperactive disorder, or autism spectrum disorder recorded in national registries.Interpretation: No evidence was found of an increased risk of deficits in motor development, executive function, or hearing in children with extreme hyperbilirubinaemia who did not have intermediate or advanced bilirubin encephalopathy.

18 January 2011 in Acta Paediatrica
Verified
Journal Article
Closed access
PDF file
RMRené Mathiasen
René Mathiasen
BHBo Mølholm Hansen
Bo Mølholm Hansen
JFJulie Forman
Julie Forman
LKLars Vedel Kessing
Lars Vedel Kessing
GGGorm Greisen
Gorm Greisen